{
  "id": 8355207,
  "title": "Tempus AI CEO, data Ryan Fukushima sells $49,000 in stock",
  "url": "https://urgent.news/2026/09/19/tempus-ai-ceo-data-ryan-fukushima-sells-49-000-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-19T01:45:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/tempus-ai-ceo-data-ryan-fukushima-sells-49000-in-stock-93CH-4908031"
  },
  "original_language": "en",
  "account": "Tempus AI CEO Ryan Fukushima, also known as Data of the company, sold 700 shares of Tempus AI Inc. (NASDAQ:TEM) stock on September 16, 2026, for a total of $49,000. Each share was sold at $70.0. Since the sale, the stock price has risen to $77.84, marking a 31.9% increase over the past week.\n\nThe transaction was executed under a Rule 10b5-1 trading plan, approved by Fukushima's spouse on March 12, 2026. After the sale, Fukushima remains the owner of 562,463 shares of Class A Common Stock, while his spouse holds an additional 15,874 shares indirectly. According to InvestingPro, the stock is currently considered overvalued, making it part of the platform's Most Overvalued list.\n\nTempus AI's stock is currently under scrutiny from various analysts. H.C. Wainwright raised its price target for the company to $66, maintaining a Buy rating, citing positive Phase 3 results from Merck and Moderna as favorable for Tempus AI's potential acquisition of Personalis. Similarly, Piper Sandler upgraded Tempus AI to Overweight from Neutral, setting a price target of $76, emphasizing the company's growth prospects and the strategic advantages of the Personalis acquisition. Rothschild Redburn assigned a Neutral rating and a $67 price target, focusing on Tempus AI's innovative tumor-informed treatment selection tests. Lastly, Cantor Fitzgerald initiated coverage with an Overweight rating and an $80 price target, indicating substantial upside potential for the company.\n\nThese analyst updates indicate a heightened interest in Tempus AI's advancements in precision medicine and diagnostics. The article was produced with AI assistance and reviewed by an editor. For additional details, readers are directed to the source's Terms and Conditions.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Tempus AI chief accounting officer sells $529,650 in stock",
        "url": "https://urgent.news/2026/09/19/tempus-ai-chief-accounting-officer-sells-529-650-in-stock",
        "published": "2026-09-19T01:45:55.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}